- }				
ncerCare	Date:		Patient La	bel
McDermot Avenue nnipeg, Manitoba nada R3E 0V9	Re: Follow-Up Care for			
Taché Avenue nnipeg, Manitoba nada R2H 2A6				
w.cancercare.mb.ca	Dear: Family Physician / Nurse Practitioner / Surgeon	_		
The above p	patient has completed treatment for		lymphoma a	nd has no evidence of recurrent
disease. Ac	companying this letter are two documents for your clin	ic chart tha	t the patient	has already received.
• Follow	w-Up Recommendations for	lymp	homa	·
Perso	onalized Cancer Treatment Summary			
Treatment" to The pat and follow examinate been as month to Please gives specified by the pat available service:	has also received a folder containing Lymphoma Cancooklet addressing general issues for all cancer surviverient is now being returned to you for supervision ow-up care, including blood work and physical ation as well as general medical care. She/he has sked to make an appointment with you in the next to discuss follow-up care. Inote that the "Follow-Up Recommendations" page pecific direction for you about physical examinations, hanaging test results and referring the patient back to f there is a concern of recurrence. Item remains welcome to access the support e at CCMB through Patient and Family Support is (204-787-2109).	ors, such a The pres The imp recu is b sym imp phy con pres pati	patient will of scriptions and Physicians Physicians Physicians See document ortant role in the properties of the properties of the physician ortant, as we sical recover ditions and the prention. You ent's follow-upations.	se, and emotional recovery. continue to have their cancer follow-up care d imaging organized by: at CancerCare Manitoba at the local Community Cancer Program ts are for your information to support your caring for this patient. Many cancer sent to the FP/NP first even when the patie If at the cancer centre. Your vigilance for may indicate recurrence is therefore and indicate recurrence is therefore and your support around their emotional ar your the management of their other medical meir needs for health promotion and will be sent updated information if the up care is transferred to you in the future.
CCMB well	mation for health care providers about follow-up care is balte: www.cancercare.mb.ca/followupcare/ Topics included and Topics included an		Diet & Nutri Exercise &	lymphoma patients can be found on the ition following lymphoma Activity following lymphoma Problems, Side Effects and Resources
Thank you v Sincerely,	ery much for your care and commitment to the care of	cancer pat	ients and the	eir families.
□ ССМВ М	edical Oncologist	st 🖵 Si	urgeon	☐ Family Physician in Oncology
	ollow-Up Care Plan documents are new tools created look/suggestions at transitions@cancercare.mb.ca.	oy Cancer(Care Manitob	a. Email us for further information or with V 1.9 April 2015

Cancer Question? Expert Help for Primary Care call·text ► 204-226-2262 Email ► cancerquestion@cancercare.mb.ca



Follow-Up Care Plan Part 1 Treatment Summary

Patient Label or To	day's Date:	
Name:		
Birthdate:	CR#:	

Cancer Team		Pathology						
FP or NP		☐ Lymph Node Biopsy						
Hematologist/Oncologist		Biopsy Date:						
Radiation Oncologist		Biopsy Site:						
CCMB Primary Nurse		■ Bone Marrow Biopsy and aspirate Biopsy Date:						
Primary Support Person		☐ Involved						
(name & phone)		☐ Not involved						
Nursing Station Phone:		□ Not done						
Nursing Station Frione.								
Interpreter Required:		☐ Other diagnostic procedure/biopsy						
		Date: Details:						
		Details.						
Cancer Information		Chemotherapy	Radiation					
Indolent Lymphoma		□ No Chemotherapy	□ No Radiation required					
☐ Follicular	Indolent B Cell NHL not	☐ R-CHOP (rituximab,						
□ Waldenstroms	otherwise specified	cyclophosphamide, vincristine,	☐ Radiation site:					
☐ Marginal Zone	·	doxorubicin, prednisone) BR (bendamustine + rituximab)						
☐ MALT		☐ R-CVP (rituximab, cyclophosphamide	□ Date Completed:					
Staging at the Time of D	Diagnosis	vincristine, prednisone)						
□ I □ A		☐ Maintenance rituximab	Persistent Heath					
□ □ B			Issues from					
□ III □ E		☐ Other:	Treatment					
□ IV								
Ann Arbor Staging System Stage I: one group of lymph node	c	# Cycles completed:	☐ Fatigue					
Stage II: 2 or > groups of nodes affe		Reason for stopping early:	☐ Peripheral Neuropathy (numbness, tingling or pain from					
Stage III: 2 or > groups of nodes a	_ , ,	☐ Toxicity	nerve damage)					
diaphragm	_	☐ Pt Declined	☐ Shortness of breath					
Stage IV: involvement of at least of	ne organ	☐ Other	☐ Neutropenia					
A Abanas of Daymantana		 	☐ Anemia					
A: Absence of B symptoms		Result: ☐ CR (complete response)	☐ Thrombocytopenia☐ Adverse drug/treatment					
B: Presence of B symptoms E: Extranodal involvement		☐ PR (partial response)	reactions					
L. LXII anodai involvement		☐ Stable disease	☐ Drug Effect:					
			Other:					
Diagnostic Imaging	Other Comments:	Complimentan/ N	│ ledications (include					
(Post Treatment)	Guici Commonts.		enewal requirements):					
Date:		Traditional Medicines	<u> </u>					
☐ PET scan								
☐ CT scan								
☐ Ultrasound								
☐ MUGA scan Date of Most Recent CT/PET scar	3.							
Date of Most Necell C1/FL1 Scal								



Indolent Non-Hodgkins Lymphoma 8 Year Follow-Up Tests & Appointments for:

	Last Name	, First Name
DOB:	CR#:	Date of Last Chemotherapy:

(Year 1 Follow up starts at the start of maintenance rituximab)

	(1 cai	Procedure	Health Care Provider
Year 1	+ 6 months	Medical AppointmentBlood Test	Oncologist/FPO
	+9 months	Order CT Scans for 1 year visit: Head/Neck/Chest/Abdomen/Pelvis (as applicable*)	Oncologist/FPO
	+1 year	Medical AppointmentBlood TestCT Scan Results	Oncologist/FPO
	+1 year 6 months	Medical AppointmentBlood Test	Oncologist/FPO
	+1 year 9 months	Order CT Scan for 2 year visit: Head/Neck/Chest/Abdomen/Pelvis (as applicable*)	Oncologist/FPO
Year 2	+2 years	 MAINTENTANCE RITUXIMAB COMPLETED Medical Appointment Blood Test CT Scan Results ARRANGE TRANSITION APPOINTMENT 	Oncologist/FPO
	+2 years 6 months	Medical AppointmentBlood TestDO TRANSITIONAL APPOINTMENT	Oncologist/FPO
Year 3	+3 years	Medical AppointmentBlood Test	Oncologist/FPO/Family Physician
	+3 years 6 months	Medical AppointmentBlood Test	Oncologist/FPO/Family Physician
Year 4	+4 years	Medical AppointmentBlood Test	Oncologist/FPO/Family Physician
	+4 years 6 months	Medical AppointmentBlood Test	Oncologist/FPO/Family Physician
Year 5	+5 years	Medical AppointmentBlood Test	Oncologist/FPO/Family Physician
Year 6	+6 years	Medical AppointmentBlood Test	Oncologist/FPO/Family Physician
Year 7	+7 years	Medical AppointmentBlood Test	Oncologist/FPO/Family Physician
Year 8	+8 years	Medical AppointmentBlood Test	Oncologist/FPO/Family Physician

^{*} Once CT's have documented complete remission, no further imaging is required unless relapse is suspected.



	Patient Label		
Patient Name:			
Date of Birth:		CR#:	
Diagnosis Date:	_	·	

Follow-Up Recommendations Indolent Lymphoma Patients

Year 1 Follow-up begins at the start of maintenance rituximab

	Years 3 – 5 post completion of therapy	Years 6+
Primary Care Visits (Family Physician / Nurse Practitioner): -History and focused examination: lymph nodes (pre/post auricular, cervical, supra/infraclavicular, axillary, inguinal), spleen/liver, skin exam -Patient reported B-symptoms (fever, night sweats, unintentional weight loss)	Every 6 months	Annually
Blood work: CBC, electrolytes, creatinine, liver functions including LDH TSH, T3, T4 (if previous neck radiation) SPEP (serum protein electrophoresis) for patients with Waldenstroms Macroglobulinemia Persistently * elevated LDH in conjunction with positive clinical findings may be indicative of relapsed lymphoma	Every 6 months	Annually
X-Rays, CT- US- MRI- Bone- PET Scans	NOT performed if a	nsymptomatic

Physician / Nurse Practitioner Visits

- o Encourage Vitamin D 1000-2000 IU daily.
- o Encourage patients with a lymphoma diagnosis to receive the annual influenza vaccination.
- o Most patients who are 6 months post treatment are eligible to receive the shingles vaccination. Patients with persistent immune suppression or who are taking immunosuppressant medications SHOULD AVOID this vaccine.
- Medication update including complementary therapies.
- o Encourage smoking cessation, healthy heart, sun sense, and routine cancer screening for cervical, colorectal and breast cancers. Patients treated for lymphoma are at higher risk for developing second cancers.
- o Abnormal symptoms or signs should be investigated with exam, lab and imaging.
- o Encourage patient to see MD/NP regarding any worrisome symptoms without waiting for their next regular appointment.

Common Symptoms of Relapse/Recurrence

- o Unexplained weight loss o New or enlarged lymph nodes o Drenching night sweats
- Persistent, unexplained symptoms such as shortness of breath and abdominal pain
 Recurrent infections

What to do if concerned about cancer recurrence

- o Investigate with imaging of the area (CT recommended), complete blood work and full physical exam.
- Please initiate investigations and a surgical referral to confirm pathology (when applicable) and fax a referral to the CCMB Referral Office at 204-786-0621 and indicate if patient is highly symptomatic. Patient will be contacted within 2-3 working days.

FOLLOW-UP CHECKLIST

Year		1		2		3		4		5	6+
Month	6	12	6	12	6	12	6	12	6	12	12
History & Physical											
Blood work											